Outcomes in diabetics undergoing revascularization The long and the short of it* by Mathew, Verghese & Holmes, David R
EDITORIAL COMMENT
Outcomes in Diabetics
Undergoing Revascularization
The Long and the Short of It*
Verghese Mathew, MD, FACC,
David R. Holmes, JR, MD, FACC
Rochester, Minnesota
Diabetes mellitus, a major determinant of cardiovascular
events, portends an adverse prognosis in patients with
coronary artery disease regardless of treatment strategy.
Among patients undergoing coronary revascularization pro-
cedures, the Bypass Angioplasty Revascularization Investi-
gation (BARI) trial (1) demonstrated an unfavorable inter-
action between diabetes and an initial strategy of
percutaneous transluminal coronary angioplasty (PTCA) in
patients with multivessel disease requiring revascularization,
with an increased all-cause mortality of 34.7% at five years
in the PTCA group. However, even with coronary artery
bypass graft surgery (CABG), mortality was 19.1% at five
years, still greater than the 9.5% and 10.3% five-year
mortality rates for PTCA and CABG, respectively, in
nondiabetics. Although this finding of inferior outcome
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with PTCA compared to CABG is often extrapolated
broadly, resulting in the perception that CABG is the
default revascularization modality for all diabetics, there are
some confounding issues. Other available evidence (2–4)
demonstrates that diabetes is not an absolute contraindica-
tion to percutaneous coronary intervention (PCI), and
careful patient selection for each revascularization modality
can result in comparable outcomes (Table 1). The under-
standing of this concept may be enhanced by an examina-
tion of the factors that affect both short- and long-term
outcomes among diabetics undergoing coronary revascular-
ization.
CABG IN DIABETICS
In the BARI trial, CABG was found to provide superior
long-term survival in diabetics with multivessel coronary
disease compared to PTCA (1). Although this was not a
prespecified analysis and was not reproduced in the other
randomized trials of revascularization for multivessel dis-
ease, the finding seems valid based on the vascular biology of
diabetes, which is associated with abnormalities of throm-
bosis/fibrinolysis and endothelial dysfunction (5). However,
data from the BARI registry (2) and the Duke database (3)
make it clear that careful clinical selection of patients for
either revascularization strategy results in comparable out-
comes, acknowledging that patients referred for CABG had
more advanced atherosclerosis and reduced ventricular func-
tion compared to PCI patients.
Short-term outcome. Despite the demonstrated superior-
ity of CABG over PTCA in the BARI randomized trial,
CABG obviously is associated with operative risk. The
reported influence of diabetes on operative risk is variable,
with some studies reporting excess mortality in diabetics
(6–8), and others reporting comparable short-term survival
in nondiabetics (9,10), although the independent effect of
diabetes on short-term survival is less clear. Several studies,
however, demonstrate increased perioperative morbidity
among diabetics, including neurologic complications (8),
renal dysfunction (7) and wound infection (7,11), with
sternal wound infection being of particular concern when
both mammary arteries are utilized as conduits.
In the current issue of the Journal, Carson et al. (12)
performed an analysis of 146,786 patients undergoing iso-
lated CABG operations from the 1997 Society of Thoracic
Surgeons Registry (41,663 diabetics and 105,123 nondia-
betics) to determine the effect of diabetes on 30-day
operative mortality. Absolute mortality rates were higher in
diabetics (3.74% vs. 2.7%); when adjusting for multiple
differences in baseline characteristics with models that
included demographic, clinical, procedural and periproce-
dural treatment variables, diabetes was independently cor-
related with 30-day mortality (odds ratio [OR] 1.23; 95%
confidence intervals [CI] 1.15 to 1.32), comparable to the
excess mortality effect of female gender and peripheral
arterial disease, but less than the effect of pre-existing renal
failure, preoperative cardiogenic shock and redo surgery.
The increased mortality effect was greatest among diabetics
treated with insulin (OR 1.39; 95% CI 1.27 to 1.52) and less
pronounced, but still significant, in patients treated with
oral hypoglycemic agents (OR 1.13; 95% CI 1.04 to 1.23).
Importantly, although death was attributable to cardiac
causes (which generally includes ischemia due to graft
failure, left ventricular failure and dysrhythmia) in approx-
imately two-thirds of all patients, neurologic events led to
9.64% of nondiabetic perioperative deaths and 12.14% of
diabetic perioperative deaths.
Although the investigators hypothesize that volume/
electrolyte shifts, perioperative hyperglycemia and the po-
tentially negative inotropic and arrhythmogenic effects of
free fatty acids may help to explain the excess mortality in
diabetics, these factors would in general be expected to affect
cardiac mortality, which somewhat surprisingly in this study
(12) was lower in diabetics than in nondiabetics (65.8% vs.
68.3%). This suggests that the excess short-term mortality
in diabetics undergoing CABG is largely due to increased
noncardiac mortality, including neurologic, renal, infectious
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and perhaps other causes. Whether heightened vigilance
and awareness of these issues in the perioperative period can
reduce morbidity and mortality in diabetics is not clear.
Although the use of off-pump techniques has been sug-
gested to reduce the neurologic sequelae of extracorporeal
circulatory assist devices, the benefits in this regard may
disappear during long-term follow-up (13). As the morbid-
ity and mortality rates appear highest in insulin-treated
patients, this group may warrant the highest level of
attention.
Long-term outcome. Among patients undergoing CABG,
diabetics have worse long-term survival than nondiabetics.
The observation that insulin-requiring patients fare worse
than oral-agent–treated patients is also apparent in the
long-term outcome (all-cause mortality) of diabetics under-
going CABG in the BARI randomized trial (2), but this
may signify that insulin treatment is a marker of more
advanced state and/or longer duration of diabetes, resulting
in more advanced atherosclerosis, rather than an indepen-
dent effect of insulin therapy. Other factors also influence
long-term event-free survival in diabetics undergoing
CABG. Importantly, the survival advantage of CABG over
PCI in BARI diabetics was exclusively in those patients who
received an internal mammary arterial graft; those who only
received vein grafts had outcomes similar to PTCA patients
(1). Although BARI demonstrated improved long-term
survival in diabetics undergoing CABG rather than PTCA,
in the more recent Arterial Revascularization Therapics
Study (14), which compared stent implantation (with a low
rate of glycoprotein IIB/IIIA antagonist use) to CABG for
multivessel disease, mortality of patients undergoing CABG
was similar to that observed in PCI patients, although only
one-year mortality has been reported thus far.
PCI IN DIABETICS
Short-term outcome. Although comparing short-term
outcome (in-hospital or 30 day) after PCI in diabetics versus
nondiabetics has not been a primary focus of coronary
interventional studies, the majority of available evidence
would suggest that periprocedural mortality rates are com-
parable (1,15,16), although diabetes increases the likelihood
of postprocedural renal dysfunction including hemodialysis
(17,18), and it may increase the occurrence of stroke (17).
Long-term outcome. In contrast to short-term events,
long-term outcome after PCI in diabetics has consistently
been shown to be worse than in nondiabetics. The higher
rate of restenosis in diabetics compared to nondiabetics is
due to an exaggerated neointimal response after PCI (19),
greater negative vessel remodeling (20), increased platelet
aggregability and reduced fibrinolytic mechanisms (5). Al-
though the use of intracoronary stents has been reported to
negate the adverse effect of diabetes on restenosis (20), most
series report that diabetics have an increased likelihood of
repeat revascularization even when utilizing stents (21,22),
underscoring the influence of exaggerated neointimal hy-
perplasia in this population.
The increased risk of restenosis after PCI in diabetics,
including a higher rate of occlusive restenosis (23), translates
into increased rates of target lesion-related ischemic events.
In diabetics undergoing PTCA, restenosis manifesting as
total vessel occlusion occurred in 13% of treated lesions and
was associated with both a reduction in left ventricular
ejection fraction at six-month follow-up (23) and with
reduced long-term survival compared to patients with no
restenosis or nonocclusive restenosis (24). This link between
increased vessel reocclusion and reduction in left ventricular
function, and the correlation with long-term mortality, may
Table 1. Survival After PTCA/CABG in Diabetic Patients
Study
5-Year
Mortality p Value
Relative Risk
of Death (5-Year)
(PCI vs. CABG)
BARI randomized trial (2)
PTCA 34.5% 0.0024 1.87
CABG 19.4%
BARI registry (2)
PTCA 14.4% 0.86 1.10
CABG 14.9%
Duke database (3)
PTCA 24% NA NA
CABG 26%
Northern New England Study (4)
2-vessel disease NA 0.21 1.33
3-vessel disease 0.038 2.02
ARTS (14)
Stent 2.5%* NA NA
CABG 2.8%*
*One-year mortality.
ARTS  Arterial Revascularization Therapies Study; BARI  Bypass Angioplasty Revascularization Investigation;
CABG  Coronary artery bypass graft surgery; NA  Not available; PCI  percutaneous coronary intervention; PTCA 
percutaneous transluminal coronary angioplasty.
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in part explain the poor outcome observed in diabetics after
PTCA alone.
All is not lost, however, with respect to diabetics and
PCI. In this issue of the Journal, Van Belle et al. (25)
demonstrate a highly beneficial, durable effect of stent
implantation compared to PTCA in diabetics. By matching
157 diabetics and 157 nondiabetics for gender, diabetes
treatment regimen (insulin or oral agent), stenosis location,
reference diameter and minimal lumen diameter, with other
baseline characteristics being similar between the two
groups, the investigators demonstrated that six-month re-
stenosis and vessel occlusion was significantly reduced by
utilizing stents (27% vs. 62%, p  0.0001 and 4% vs. 13%,
p  0.005). The PTCA patients in this cohort had a
significant reduction in ejection fraction at six months
(2.4  10.9%, p  0.02), whereas stent patients did not,
presumably owing to the importance of occlusive restenosis
previously documented by these investigators (23). Stent
implantation was also associated with reduced death/
myocardial infarction (14.8% vs. 26%, p  0.02) and need
for target lesion revascularization (TLR) (21% vs. 40.6%,
p  0.0002).
Although the need for any repeat revascularization was
reduced with stents (35.4% vs. 52.1%, p  0.001), the
difference between these figures and the rates of TLR
approximates the need for nontarget lesion revascularization
during the course of follow-up, and it serves as a reminder
of the systemic, ubiquitous nature of atherosclerosis. Indeed,
it has been demonstrated that diabetics are more likely to
develop new coronary lesions at untreated sites after PTCA
(26), particularly in instrumented vessels. It has also been
demonstrated that the appearance of new coronary lesions
correlates with worse long-term mortality among BARI
PTCA patients (relative risk 1.27 for every new lesion found
on five-year protocol angiography) (27). Furthermore, pa-
tients with diabetes undergoing PTCA in BARI had a
significantly greater myocardial jeopardy index at five-year
protocol or nonprotocol angiography, a finding not observed
in CABG patients (28).
It seems unlikely, therefore, that optimizing only the
target lesion utilizing stents, glycoprotein IIB/IIIA antago-
nists (29), or even drug-coated stents (30) will alone
eliminate the excess risk associated with diabetes in coronary
disease patients; although these measures appear effective in
reducing TLR and target lesion-related adverse events,
persistent long-term efforts at optimizing the patient with
strict glycemic control, treatment of concomitant cardiovas-
cular risk factors including aggressive lipid-lowering with
statins, and long-term antiplatelet therapies seem prudent
(though yet unproven) to complement periprocedural mea-
sures.
The impact of diabetes treatment also bears consider-
ation. The adverse effect of sulfonylureas on outcomes after
myocardial infarction has been documented (31,32), as well
as the potential for an adverse long-term effect of insulin
treatment after PCI (16,33), although it is possible that
requiring insulin may be merely a marker of more advanced
diabetes rather than an independent adverse effect of treat-
ment. The potential antirestenotic effect of the newer
insulin-sensitizing agents such as troglitazone is of interest
(34) and merits further clinical investigation. Whether
treatment of diabetes with an insulin-sensitizing regimen or
an insulin-providing regimen is preferred will be further
elucidated in the BARI 2D study.
In addition, BARI 2D will also address the question of
whether revascularization in diabetics carries any advantage
over medical therapy, an issue that has not been explicitly
demonstrated. However, the use of an early invasive strategy
in diabetic patients with non–ST-elevation acute coronary
syndromes appears to be superior than an early noninvasive
strategy as demonstrated in the Fragmin and Fast Revascu-
larization during Instability in Coronary Artery Disease (35)
and Treat Angina with Aggrastat and Determine Cost of
Therapy with an Invasive or Conservative Strategy–
Thrombolysis In Myocardial Infarction 18 (36) trials, allay-
ing some of the concern of perceived excess risk associated
with an invasive approach in diabetics.
REVASCULARIZATION IN
DIABETICS: WHAT TO DO NOW?
Despite the realization that diabetes is associated with
greater adverse events than nondiabetes regardless of revas-
cularization strategy, it is clear that diabetics will continue to
require coronary revascularization; while ongoing and future
studies may help clarify the role of revascularization and
optimize the short- and long-term outcome of diabetics
undergoing revascularization, how should these patients be
managed at present? In diabetic patients with single-vessel
disease, the use of revascularization should be considered for
relief of ischemia, treatment of angina pectoris, and im-
provement in quality of life, just as in nondiabetic patients.
The optimal strategy for diabetics with single-vessel disease
requiring revascularization has not been specifically studied,
although PCI would seem reasonable as an initial strategy if
technically feasible. In multivessel disease, careful patient
selection for one revascularization strategy versus the other
is essential; patients with more extensive atherosclerosis
(many lesions, diffuse multivessel disease, chronic occlu-
sions, multiple complex lesions) are better suited for
CABG. The presence of multivessel disease does not
preclude PCI, particularly when lesions are discrete and
approachable with a high likelihood of success and not
associated with excessive likelihood of restenosis.
In borderline situations, or situations where the perceived
advantage of CABG over PCI is less compelling, other
comorbidities should also be taken into account; for exam-
ple, in patients with a history of stroke or other evidence of
significant cerebrovascular disease, PCI may hold an advan-
tage over CABG. Regardless, if PCI is the chosen therapy,
optimizing angiographic results, and the use of stents and
glycoprotein IIB/IIIA antagonists should be strongly con-
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sidered. Finally, despite the revascularization strategy uti-
lized, aggressive treatment of diabetes and concomitant
cardiovascular risk factors must be emphasized.
As is true with all patients, but particularly in those with
complex disease processes, such as diabetes mellitus, as
Alexander of Tralles observed, “The physician should look
upon the patient as a besieged city and try to rescue him
with every means that art and science place at his com-
mand.”
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